# A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

> **NCT06511570** · PHASE1 · COMPLETED · sponsor: **Acumen Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** sabirnetug (ACU193)
- **COMBINATION_PRODUCT:** Sabirnetug + rHuPH20

## Key facts

- **NCT ID:** NCT06511570
- **Lead sponsor:** Acumen Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-25
- **Primary completion:** 2024-09-17
- **Final completion:** 2024-09-17
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06511570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06511570, "A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06511570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*